Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy

In Italy, 128,948 confirmed cases and 15,887 deaths of people who tested positive for SARS-CoV-2 were registered as of 5 April 2020. Ending the global SARS-CoV-2 pandemic requires implementation of multiple population-wide strategies, including social distancing, testing and contact tracing. We propose a new model that predicts the course of the epidemic to help plan an effective control strategy. The model considers eight stages of infection: susceptible (S), infected (I), diagnosed (D), ailing (A), recognized (R), threatened (T), healed (H) and extinct (E), collectively termed SIDARTHE. Our SIDARTHE model discriminates between infected individuals depending on whether they have been diagnosed and on the severity of their symptoms. The distinction between diagnosed and non-diagnosed individuals is important because the former are typically isolated and hence less likely to spread the infection. This delineation also helps to explain misperceptions of the case fatality rate and of the epidemic spread. We compare simulation results with real data on the COVID-19 epidemic in Italy, and we model possible scenarios of implementation of countermeasures. Our results demonstrate that restrictive social-distancing measures will need to be combined with widespread testing and contact tracing to end the ongoing COVID-19 pandemic. A new epidemiological model, termed SIDARTHE, distinguishes between diagnosed and undiagnosed cases of SARS-CoV-2 infection, as well as modeling effects of social distancing and widespread testing, to predict possible outcomes of the COVID-19 epidemic in Italy.

[1]  W. O. Kermack,et al.  A contribution to the mathematical theory of epidemics , 1927 .

[2]  A. J. Hall Infectious diseases of humans: R. M. Anderson & R. M. May. Oxford etc.: Oxford University Press, 1991. viii + 757 pp. Price £50. ISBN 0-19-854599-1 , 1992 .

[3]  O. Diekmann,et al.  Mathematical Epidemiology of Infectious Diseases: Model Building, Analysis and Interpretation , 2000 .

[4]  Herbert W. Hethcote,et al.  The Mathematics of Infectious Diseases , 2000, SIAM Rev..

[5]  F. Brauer,et al.  Mathematical Models in Population Biology and Epidemiology , 2001 .

[6]  Michelle M. Packard,et al.  Prior Infection and Passive Transfer of Neutralizing Antibody Prevent Replication of Severe Acute Respiratory Syndrome Coronavirus in the Respiratory Tract of Mice , 2004, Journal of Virology.

[7]  M. E. Alexander,et al.  Modelling strategies for controlling SARS outbreaks , 2004, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[8]  C. Furlanello,et al.  Mitigation Measures for Pandemic Influenza in Italy: An Individual Based Model Considering Different Scenarios , 2008, PloS one.

[9]  Maimuna S. Majumder,et al.  Estimation of MERS-Coronavirus Reproductive Number and Case Fatality Rate for the Spring 2014 Saudi Arabia Outbreak: Insights from Publicly Available Data , 2014, PLoS currents.

[10]  Pejman Rohani,et al.  Avoidable errors in the modelling of outbreaks of emerging pathogens, with special reference to Ebola , 2014, Proceedings of the Royal Society B: Biological Sciences.

[11]  R. Webby,et al.  Longitudinal study of Middle East Respiratory Syndrome coronavirus infection in dromedary camel herds in Saudi Arabia, 2014–2015 , 2017, Emerging Microbes &Infections.

[12]  K. Subbarao,et al.  Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody , 2017, PLoS pathogens.

[13]  P. Spigaglia,et al.  Microbiological characteristics of human and animal isolates of Clostridioides difficile in Italy: Results of the Istituto Superiore di Sanità in the years 2006-2016. , 2019, Anaerobe.

[14]  T. Velavan,et al.  The COVID‐19 epidemic , 2020, Tropical medicine & international health : TM & IH.

[15]  Dan Xu,et al.  Positive RT-PCR Test Results in Patients Recovered From COVID-19. , 2020, JAMA.

[16]  H. Fineberg Ten Weeks to Crush the Curve. , 2020, The New England journal of medicine.

[17]  H. G. Liu,et al.  [Cause analysis and treatment strategies of "recurrence" with novel coronavirus pneumonia (covid-19) patients after discharge from hospital]. , 2020, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.

[18]  Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China , 2020, Nature Medicine.

[19]  Yuyi Wang,et al.  Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID‐19) implicate special control measures , 2020, Journal of medical virology.

[20]  Maria Elena Bottazzi,et al.  The SARS-CoV-2 Vaccine Pipeline: an Overview , 2020, Current Tropical Medicine Reports.

[21]  P. Vollmar,et al.  Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany , 2020, The New England journal of medicine.

[22]  L. Meyers,et al.  Serial Interval of COVID-19 among Publicly Reported Confirmed Cases , 2020, Emerging infectious diseases.

[23]  G. Remuzzi,et al.  COVID-19 and Italy: what next? , 2020, The Lancet.

[24]  Francesco Casella Can the COVID-19 epidemic be managed on the basis of daily data? , 2020, ArXiv.

[25]  Anne Kimball,et al.  Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility — King County, Washington, March 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[26]  Bo Diao,et al.  Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19) , 2020, Frontiers in Immunology.

[27]  Min Kang,et al.  SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients , 2020, The New England journal of medicine.

[28]  Yongli Cai,et al.  A conceptual model for the coronavirus disease 2019 (COVID-19) outbreak in Wuhan, China with individual reaction and governmental action , 2020, International Journal of Infectious Diseases.

[29]  Victor M Corman,et al.  Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[30]  J. Dowd,et al.  Demographic science aids in understanding the spread and fatality rates of COVID-19 , 2020, Proceedings of the National Academy of Sciences.

[31]  P. Klepac,et al.  Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts , 2020, The Lancet Global Health.

[32]  Julian Peto,et al.  Covid-19 mass testing facilities could end the epidemic rapidly , 2020, BMJ.

[33]  Shaoqiang Li,et al.  Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosis , 2020, Journal of medical virology.

[34]  R. Jiang,et al.  Clinical features of pediatric patients with COVID-19: a report of two family cluster cases , 2020, World Journal of Pediatrics.

[35]  P. Klepac,et al.  Early dynamics of transmission and control of COVID-19: a mathematical modelling study , 2020, The Lancet Infectious Diseases.

[36]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[37]  N. Linton,et al.  Serial interval of novel coronavirus (COVID-19) infections , 2020, International Journal of Infectious Diseases.

[38]  Wu Zhong,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[39]  Potential Therapeutic Agents for COVID-19 Based on the Analysis of Protease and RNA Polymerase Docking , 2020 .

[40]  J. Hyman,et al.  Short-term Forecasts of the COVID-19 Epidemic in Guangdong and Zhejiang, China: February 13–23, 2020 , 2020, Journal of clinical medicine.

[41]  Yunpeng Ji,et al.  Potential association between COVID-19 mortality and health-care resource availability , 2020, The Lancet Global Health.

[42]  L. Yang,et al.  Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak , 2020, International Journal of Infectious Diseases.

[43]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[44]  C. Anastassopoulou,et al.  Data-based analysis, modelling and forecasting of the COVID-19 outbreak , 2020, PloS one.

[45]  Michael McAleer,et al.  Risk Management of COVID-19 by Universities in China , 2020, Journal of Risk and Financial Management.

[46]  D. Cummings,et al.  Novel coronavirus 2019-nCoV: early estimation of epidemiological parameters and epidemic predictions , 2020, medRxiv.

[47]  Liang Peng,et al.  Recurrence of positive SARS-CoV-2 RNA in COVID-19: A case report , 2020, International Journal of Infectious Diseases.

[48]  A. H. Y. Ma,et al.  COVID-19 Transmission Within a Family Cluster by Presymptomatic Carriers in China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  Yan Bai,et al.  Presumed Asymptomatic Carrier Transmission of COVID-19. , 2020, JAMA.

[50]  Zheng Zhao,et al.  Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures , 2020, The Lancet.